This post was originally published on this site Poteligeo (mogamulizumab), an approved treatment for relapsed or refractory adult T-cell leukemia-lymphoma (ATL) patients in Japan, is also safe and effective in a real-world clinical setting, a postmarketing surveillance study found. The study, “Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma,” was published in…

This post was originally published on this site U.S. regulators have granted orphan drug status to TP Therapeutics’ TPX-0005 as a treatment for non-small cell lung cancers with certain gene mutations, according to a company press release. The Federation Drug Administration decision is aimed at accelerating TPX-0005’s approval. The designation will also give the company seven years of…

This post was originally published on this site Patients with an aggressive kind of skin cancer called Merkel cell carcinoma appear to have better responses and live longer when given the PD-1 inhibitor Keytruda (pembrolizumab), compared to previous patients given first-line chemotherapy, a Phase 2 clinical trial shows. The findings support Keytruda’s recent accelerated approval for…

This post was originally published on this site The U.S. Food and Drug Administration has granted priority review to Merck‘s application requesting the approval of Keytruda (pembrolizumab) in combination with Inlyta (axitinib) for the initial treatment of advanced renal cell carcinoma (RCC) patients, with a final decision expected June 20, the company announced. The application…

This post was originally published on this site The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), has recommended the approval of Keytruda (pembrolizumab) in combination with chemotherapy for the initial treatment of metastatic squamous non-small cell lung cancer (NSCLC) patients. The CHMP’s opinion was based on clinical evidence from the KEYNOTE-407 Phase…

This post was originally published on this site Merck KGaA and GlaxoSmithKline (GSK) are working together to develop and commercialize the immunotherapy candidate M7824 (bintrafusp alfa) as a potential treatment for multiple, difficult-to-treat types of cancer. M7824 is being developed by Merck KGaA, which operates as by EMD Serono in the U.S. and Canada, and will…

This post was originally published on this site Eureka Therapeutics is planning a Phase 1/2 clinical trial in the United States to explore the safety and effectiveness of its investigational T-cell therapy ET140202 in patients with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer. The announcement comes after the U.S. Food and…

This post was originally published on this site While my doctor’s fingers massaged my breasts and cradled my hard, almond-sized lump, we had a peculiar conversation. She was from the Bay Area but traveled to tiny Lakeport for a brief assignment. My husband and I discovered the lump the previous evening in a surprising, romance-busting…

This post was originally published on this site Reducing the interval between chemotherapy treatment cycles or administering chemotherapy medications sequentially at higher doses, rather than simultaneously at lower doses, increases treatment efficacy and decreases the risk of breast cancer recurrence and death, a study suggests. The study, “Increasing the dose intensity of chemotherapy by more…

This post was originally published on this site Plerixafor — approved for the treatment of lymphoma and multiple myeloma —  decreases tumor fibrosis and improves immunotherapy response in a mouse model of metastatic breast cancer, a study finds. The study, “Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer,” was published…

This post was originally published on this site More than 600 young breast cancer survivors will gather in Austin, Texas, for the 4th Annual Young Survival Coalition (YSC) Summit. For such survivors, it’s the only national conference. In addition to those diagnosed with breast cancer before their 41st birthday, the March 8-10  YSC-sponsored event targets “co-survivors”…

This post was originally published on this site By targeting small regulatory molecules called microRNAs (miRNAs), researchers were able to reprogram breast cancer cells and render them sensitive to HER2-targeting medicines, such as Herceptin (trastuzumab) and Kadcyla (ado-trastuzumab emtansine), a study shows. The study, “A Designed Small Molecule Inhibitor of a Non-Coding RNA Sensitizes HER2 Negative Cancers to…